Brodalumab

Drug Profile

Brodalumab

Alternative Names: AMG-827; IL-17R mAb; KHK-4827; Kyntheum; LP 0160; LUMICEF; Siliq

Latest Information Update: 13 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Developer Amgen; AstraZeneca; Kyowa Hakko Kirin; Valeant Pharmaceuticals International
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 17 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Erythrodermic psoriasis; Plaque psoriasis; Psoriatic arthritis; Pustular psoriasis
  • Phase III Spondylarthritis
  • Phase I Systemic scleroderma
  • Discontinued Asthma; Crohn's disease; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Plaque-psoriasis in New Zealand (SC, Injection)
  • 12 Oct 2017 Additional efficacy data from the phase III AMAGINE-1 and AMAGINE-2 trials in Plaque psoriasis released by Valeant Pharmaceuticals
  • 14 Sep 2017 Efficacy and safety data from the phase III AMAGINE-2 extension study in Plaque psoriasis released by LEO Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top